Allergy, Anaphylaxis, and Angioedema


Key Concepts

  • Anaphylaxis is a life-threatening systemic allergic (or nonallergic) reaction of acute onset and multiorgan involvement in which timely recognition and treatment remain essential.

  • A history of sudden urticarial rash accompanied by respiratory difficulty, abdominal pain, or hypotension, strongly favors the diagnosis of anaphylaxis.

  • The recommended treatment algorithm for anaphylaxis is shown in Box 106.7 .

    BOX 106.7
    Treatment Algorithm for Anaphylaxis
    D 5 W, 5% dextrose in water; IM, intramuscular; IV, intravenous.

    Emergency Measures (Taken Simultaneously)

    • Remove any triggering agent.

    • Place the patient in the supine position.

    • Begin cardiac monitoring, pulse oximetry, and blood pressure monitoring.

    • Begin supplemental oxygen if indicated.

    • Establish large-bore IV lines (e.g., 16 or 18 gauge preferred).

    • Ensure a patent airway.

    • Be prepared for endotracheal intubation with or without rapid sequence intubation.

    • Be prepared to use an adjunct airway technique (e.g., awake fiberoptic intubation, surgical airway).

    • Start a rapid infusion of isotonic crystalloid (normal saline):

      • Adults: 1000 mL IV in the first 5 min in the adult (several liters of normal saline may be required), titrated to response

      • Pediatrics: 20–30 mL/kg IV increments

    Anaphylaxis Treatment Medications

    First-Line Agent

    • Epinephrine is the first-line medication and should be given immediately at the first suspicion of an anaphylactic reaction.

      • Adult: 0.3–0.5 mg IM (1 mg/mL concentration) in anterolateral thigh every 5–10 minutes as necessary

      • Pediatric: 0.01 mg/kg IM (1:1000 concentration) in anterolateral thigh every 5–10 minutes as necessary

    • Alternatively, epinephrine (EpiPen, 0.3 mL; or EpiPen Jr, 0.15 mL) can be administered into the anterolateral thigh

    Second-Line Agents (Should Not Precede the Administration of Epinephrine)

    Antihistamines

    • Diphenhydramine:

      • Adults: 50 mg IV or 50 mg oral

      • Pediatric: 1 mg/kg IV or oral

    • Famotidine:

      • Adult: 40 mg IV (40 mg oral)

      • Pediatric: 0.5 mg/kg IV or oral

    Aerosolized Beta-Agonists (if Bronchospasm Is Present)

    • Adult:

      • Albuterol: 2.5 mg, diluted to 3 mL of normal saline; may be repeated as needed or continuous

      • Ipratropium: 0.5 mg in 3 mL of normal saline; may be repeated as necessary

    • Pediatric:

      • Albuterol: 2.5 mg, diluted to 3 mL of normal saline; may be repeated as needed or continuous

      • Ipratropium: 0.25 mg in 3 mL of normal saline; may be repeated as necessary

    Glucocorticoids (No Benefit in the Acute Management)

    • Methylprednisolone:

      • Adult: 125–250 mg IV

      • Pediatric: 1–2 mg/kg IV

    • Prednisone/prednisolone:

      • Adult: 40–60 mg oral

      • Pediatrics: 1–2 mg/kg oral

    Refractory Hypotension

    • Consider continuous IV epinephrine drip (dilute 1 mg (1 mg/mL concentration) in 1000 mL of normal saline or D 5 W to yield a concentration of 1 μg/mL)

    • Adults: 1–10 μg/min IV (titrated to desired effect)

    • Pediatrics: 0.1–1.5 μg/kg/min IV (titrated to desired effect)

    Other Adjunctive Vasopressors to Consider

    • Dopamine: 5–20 μg/kg/min continuous IV infusion (titrated to the desired effect)

    • Norepinephrine: 0.05–0.5 μg/kg/min (titrated to desired effect)

    • Phenylephrine: 1–5 μg/kg/min (titrated to desired effect)

    • Vasopressin: 0.01–0.4 units/min (titrated between 0.01–0.04 units/min)

    Patients Receiving Beta-Blockade

    • Glucagon: 1–5 mg IV over 5 min, followed by 5–15 μg/min continuous IV infusion

  • Epinephrine is the first-line treatment in patients with anaphylaxis and should be given immediately. There are no absolute contraindications to the use of epinephrine in the setting of anaphylaxis.

  • Antihistamines and corticosteroids are second- and third-line agents in the management of anaphylaxis and should not replace or precede epinephrine.

  • Consider prolonged observation or admission for patients who (1) experience protracted anaphylaxis, hypotension, airway involvement, or unknown trigger; (2) receive IV epinephrine or more than one dose of IM epinephrine; or (3) have poor outpatient social support.

  • Patients discharged after an anaphylactic event should be prescribed self-injectable epinephrine devices and instructed on use, encouraged to develop an emergency action plan, and referred to an allergist/immunologist.

  • Patients with refractory hypotension may require a continuous IV epinephrine infusion or glucagon in patients with coexisting beta-adrenergic blockade).

  • Non-histaminergic angioedema (nonallergic angioedema) does not typically respond to epinephrine and antihistamines, though they should be considered at initial presentation. Newer drugs, including icatibant, ecallantide, and human or recombinant C1 esterase inhibitor, have been approved for use in hereditary angioedema (HAE). Fresh frozen plasma (FFP) has been used with varying success in HAE, acquired C1 esterase inhibitor deficiency (ACID), and angiotensin-converting enzyme (ACE) inhibitor-induced angioedema.

Allergy

Foundations

Background and Terminology

The prevalence of allergic disease has significantly increased over the past several decades, particularly in developed societies. It is currently estimated that 30% of the worldwide population suffer from some component of allergy, including 5% to 8% with food allergies. This has contributed to increased financial burdens on our health care systems and morbidity in affected individuals. This is largely attributed to changes in lifestyle, diet, antibiotic use, smaller families, and the “hygiene hypothesis,” which centers around decreased microbial exposure in developed countries. ,

The human immune system comprises cellular and humoral components working together in a highly complex and coordinated fashion to achieve the primary goal of protecting the human host from potentially harmful offenders. The immune system, however, can overreact to otherwise harmless agents, producing an inappropriate response that may be harmful to the host, thereby giving rise to allergy or allergic diseases. These hypersensitivity reactions are manifested in clinical symptoms ranging from nuisance-level to fatal. For practical purposes, the term allergy is used in this chapter to refer to mast cell–mediated hypersensitivity reactions. For most allergic diseases to occur, predisposed individuals require exposure to allergens through sensitization. Substances that elicit an allergic reaction are referred to as allergens, and those that elicit an antibody response are termed antigens.

On the allergic continuum, there are several important allergic syndromes ( Fig. 106.1 ). Urticaria (wheels, hives) is a common allergic reaction to foods, drugs, temperature changes, or physical stimuli. It is clinically characterized by a raised central swelling of variable size with surrounding reflex erythema, combined with an itching or burning sensation, with the skin typically returning to its baseline appearance within 30 minutes to 24 hours.

Fig. 106.1, Severity Spectrum of Allergic Disease.

Angioedema is characterized by sudden swelling of the subcutaneous or mucous membranes and tends to be more painful than pruritic. In general, it is slower to resolve compared to urticaria, and if the tongue or larynx is involved, it can result in airway compromise. Angioedema can occur through one of two different mechanisms. Allergic (histaminergic) angioedema occurs in response to exposure to foods, drugs, or physical stimuli. Nonallergic (non-histaminergic) angioedema may be hereditary (termed hereditary angioedema [HAE]) or medication-induced (e.g., angiotensin-converting enzyme [ACE] inhibitor angioedema).

At the other extreme of this allergic continuum is anaphylaxis, a life-threatening systemic reaction, characterized by acute onset and multiorgan involvement. It is a type I hypersensitivity reaction (allergic), mediated by immunoglobulin E (IgE). In its most common form, anaphylaxis is precipitated by exposure to allergens in previously sensitized individuals (immunologic). Previously, the term anaphylactoid reaction referred to a syndrome clinically similar to anaphylaxis that is not mediated by IgE (non-immunologic). Its clinical presentation and treatment are identical to that of anaphylaxis. Non-IgE (non-immunologic) reactions appear to result from direct degranulation of mast cells (and basophils) and may follow a single, first-time exposure to certain inciting agents (e.g., NSAIDs, monoclonal antibodies, local anesthetics, chemotherapeutic drugs). The World Allergy Organization (WAO) guidelines use the term anaphylaxis to refer to both IgE- and non-IgE-mediated reactions, obviating the need for the term anaphylactoid reaction, although this term is still often used . ,

Pathophysiology

Immunologic responses to antigens are coordinated by two systems: the innate immune system, and the more recently evolved adaptive immune system ( Fig. 106.2 ). The innate immune system is considered the first line of defense and is characterized by its nonspecific but rapid responses to offending agents or microbes. Its effector components include resident cells (epithelial cells, mast cells, macrophages, dendritic cells, antimicrobial proteins), infiltrative cells (natural killer cells, neutrophils, monocytes, dendritic cells), and various proteins (antimicrobial peptides, complements, cytokines, and the pathogenic pattern recognition receptor [PRR] system). The innate system responds to danger signals rapidly and nonspecifically, whereas the adaptive immune system takes time for antigen-specific cells (B and T cells) to amplify through a process known as clonal expansion to mount a specific immune response. The T and B lymphocytes are capable of recognizing a myriad of antigens through a vast library of antibodies and receptors (up to 10 15 ). , ,

Fig. 106.2, Developmental Pathways of the Immune and Hematopoietic Systems.

The adaptive and innate immune systems originate from the common pluripotential hematopoietic stem cells. When the host encounters a foreign antigen, the cellular components of the adaptive immune system interact with the cellular and protein components of the innate immune system to mount a coordinated defense aimed at neutralization of the antigen.

Mast cells, basophils, and their mediators are the central effectors in allergy and anaphylaxis. Exposure of a genetically predisposed individual to an allergen leads to the synthesis and release of allergen-specific IgE by plasma cells into the circulation. Fixation of this allergen-specific IgE to surface receptors on mast cells completes the process known as sensitization. These IgE-bearing mast cells usually reside in the mucosal surfaces, submucosal tissue (around venules), and cutaneous surfaces, where they are capable of becoming activated on re-exposure to a specific allergen. Cross-linking of the mast cell receptors by a specific multivalent allergen sets off a cascade of conformational and biochemical events, causing the degranulation of preformed mediators, subsequent generation and release of arachidonic acid metabolites, elaboration of cytokines and chemokines, and activation of the cellular components by the innate and adaptive systems. This series of events ultimately leads to the clinical syndromes of allergy and anaphylaxis ( Fig 106.3 ). , ,

Fig. 106.3, Activation of mast cells with degranulation of mast cell mediators by antigen cross-linking of adjacent immunoglobulin E (IgE) on the cell surface. PAF, Platelet-activating factor.

Classification of Reactions

The term allergy is commonly used to describe clinical illnesses produced by excessive immune responses by a normal immune system to otherwise innocuous allergens. The classic Coombs and Gell classification can be adapted to categorize these hypersensitivity reactions ( Box 106.1 ).

BOX 106.1
Gell and Coombs Classification of Immune Reactions
IgE, Immunoglobulin E; IgG, immunoglobulin G; IgM, immunoglobulin M; T H 1, type 1 helper.

Type I: Immediate Hypersensitivity

Binding of multivalent antigens to IgE on the surface of mast cells and basophils leads to degranulation of mediators. In previously sensitized individuals, the reaction develops quickly (minutes). This type of hypersensitivity reaction is seen in allergic diseases (e.g., hay fever, allergic asthma, urticaria, angioedema, and anaphylaxis). Non-immunologic (previously termed anaphylactoid) reaction refers to the direct release of preformed mediators of mast cells independent of IgE.

Type II: Cytotoxic Antibody Reaction

Antibody (IgM, IgG) binding of membrane-bound antigens leads to cytotoxicity and cell lysis of cells through the complement or mononuclear cell system (macrophages, neutrophils, and eosinophils). This type of reaction is seen in transfusion reaction and Rh incompatibility.

Type III: Immune Complex–Mediated Reaction

Binding of antibody (IgM, IgG) to antigens forms soluble immune complexes, which are deposited on vessel walls, causing a local inflammatory reaction (Arthus reaction) leading to inflammation and tissue injury. This type of reaction is seen in systemic lupus erythematosus and serum sickness (after antithymocyte globulin administration).

Type IV: Cell-Mediated Delayed Hypersensitivity

Sensitized lymphocytes (T H 1 cells) recognize the antigen, recruit additional lymphocytes and mononuclear cells to the site, and start the inflammatory reaction. No antibodies are involved. This type of reaction is seen in contact dermatitis, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.

Type I reactions (immediate hypersensitivity) are IgE mediated and account for most allergic and anaphylactic reactions. Exposure to sensitizing allergens causes mediators from mast cells and basophils to be released through both IgE-dependent and IgE-independent (direct mast cell degranulation) mechanisms. Rhinitis caused by ragweed pollen and anaphylaxis caused by foods are examples of the IgE-dependent mechanism.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here